<?xml version="1.0" encoding="utf-8"?>
    <rss version="2.0">
      <channel xmlns:content="http://purl.org/rss/1.0/modules/content/">
        <title>Transplant International | New and Recent Articles</title>
        <link>https://www.frontierspartnerships.org/journals/transplant-international</link>
        <description>RSS Feed for Transplant International | New and Recent Articles</description>
        <language>en-us</language>
        <generator>Frontiers Feed Generator,version:1</generator>
        <pubDate>2026-08-19T09:02:05.39+00:00</pubDate>
        <ttl>60</ttl>
        <item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16212</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16212</link>
        <title><![CDATA[Impact of tacrolimus peak concentration on kidney graft outcomes]]></title>
        <pubdate>2026-08-17T00:00:00Z</pubdate>
        <category>Original Research</category>
        <author>Quentin Monchal</author><author>Guillaume Claisse</author><author>Nicolas Maillard</author><author>Christophe Mariat</author>
        <description><![CDATA[Low tacrolimus (Tac) trough concentration-to-dose ratio (C0/D ratio) identifies kidney transplant patients with high level of Tac metabolization and is associated with poorer outcomes. We hypothesized that fast metabolization is associated with higher maximal Tac blood concentration (Cmax) and that Tac Cmax has a detrimental effect by itself. We retrospectively selected consecutive kidney transplant patients who (i) were treated by Tac, (ii) had systematic pharmacokinetic evaluation at 3- and 12-month posttransplant, and (iii) with a minimal follow-up of 5 years. Association between Tac Cmax/C0 with traditional transplant outcomes was analysed. 519 patients with a median follow-up of 8 years were included. Fast metabolizers displayed significantly higher median Cmax (20 vs. 17 ng/mL p < 0.001). Death-censored graft survival (DCGS) was significantly lower for patients with the highest Cmax/C0 values (Log rank, p = 0.05). In multivariate cox analysis, higher Cmax/C0 was independently associated with DCGS (HR = 1.37 [1.01; 1.87], p = 0.043). Our data support the hypothesis that exposure to high Cmax is detrimental and that fast metabolizers exhibit higher Tac Cmax even in situations where Tac C0 is not elevated. Tac formulations prone to mitigate pharmacokinetic peak could thus be particularly beneficial to fast metabolizers and should be evaluated in this indication.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16723</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16723</link>
        <title><![CDATA[ABO incompatible LRD kidney transplantation should be offered to children: results from a 33-year comparative OPTN study]]></title>
        <pubdate>2026-08-17T00:00:00Z</pubdate>
        <category>Original Research</category>
        <author>Alicia Paessler</author><author>Ioannis Loukopoulos</author><author>Pankaj Chandak</author><author>Nicos Kessaris</author><author>Jelena Stojanovic</author>
        <description><![CDATA[ABOi transplantation is a growing practice with excellent clinical outcomes. Some paediatric transplant programmes are reluctant to offer ABOi transplantation and list children on a DD waiting list. However, there are no studies directly comparing the outcomes between pediatric ABOi LD kidney transplants (LDKTx) and ABOc DD transplants (DDKTx). Data were retrieved on all pediatric kidney transplants from 1987–2020, from the United Network for Organ Sharing. Propensity score matching was used to select a control group of ABOc transplant recipients. Long term outcomes were compared between ABOi and ABOc kidney transplants and between ABOi LDKTx and ABOc DDKTx. Data were compared using chi-square test, t-test and Kaplan-Meier survival analysis. Overall, there were 70 pediatric ABOi kidney transplants meeting the study criteria. There was no significant difference in allograft (p = 0.42) and patient survival (p = 0.58) between ABOi and ABOc transplants. ABOi LDKTx had significantly lower incidence of delayed allograft function and better long-term allograft survival than ABOc DDKTx (p < 0.01, p = 0.01). ABOi transplantation has excellent long-term outcomes. ABOi LDKTx lead to better long-term outcomes than ABOc DDKTx. We recommend that ABOi transplantation from a LD should be considered prior to listing children for transplantation from a DD.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16296</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16296</link>
        <title><![CDATA[Findings and significance of early follow-up biopsies after treatment of acute rejection in kidney transplant recipients]]></title>
        <pubdate>2026-08-13T00:00:00Z</pubdate>
        <category>Original Research</category>
        <author>Amanda Ahlmark</author><author>Kaisa Ahopelto</author><author>Anne Räisänen-Sokolowski</author><author>Jouni Lauronen</author><author>Marko Lempinen</author><author>Ville Sallinen</author><author>Ilkka Helanterä</author>
        <description><![CDATA[Treatment resistant acute rejection after kidney transplantation is linked to inferior outcomes, yet many centers do not routinely perform follow-up biopsies. The optimal timing of such biopsies remains uncertain. We evaluated findings from follow-up biopsies performed ≤45 days after treatment of acute rejection and assessed their association with long-term outcomes. Adult kidney transplants performed from 01/2014 to 07/2024 were included (n = 2,420). Acute rejections were classified according to Banff criteria. T-cell–mediated rejection, including borderline TCMR changes, was treated with pulse steroids; antibody-mediated rejection was treated with steroids, intravenous immunoglobulin, and plasma exchange. Findings from follow-up biopsies taken ≤45 days after treatment of early acute rejection were correlated with graft outcomes. Of 383 patients (16%) with acute rejection within 3 months post-transplant, 221 underwent a follow-up biopsy ≤45 days. Of these, 50% were taken by protocol and 50% because of clinical reasons. In 164 cases (74%), rejection changes had resolved. At 1-year, median creatinine was 1.3 mg/dL in those without rejection, 1.6 mg/dL in patients with persistent changes, and 1.5 mg/dL in those with resolved changes. Persistent histologic rejection within 45 days was associated with inferior long-term graft survival.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16741</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16741</link>
        <title><![CDATA[Pre-transplant HbA1c and BMI are associated with long-term survival after lung transplantation]]></title>
        <pubdate>2026-08-13T00:00:00Z</pubdate>
        <category>Letter to the Editor</category>
        <author>Zsofia Rosselli</author><author>Luca Saccarello</author><author>Andrea Macedo</author><author>Thomas Gaisl</author><author>Carolin Steinack</author><author>Fabrizio Pumo</author><author>Nail Atasayar</author><author>Georg Lang</author><author>Ömer Senbaklavaci</author><author>Isabelle Opitz</author><author>Irina Lea Dubach</author><author>Silvia Ulrich</author><author>Julian Müller</author><author>René Hage</author><author>Macé Matthew Schuurmans</author>
        <description></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16562</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16562</link>
        <title><![CDATA[“Innovative diagnostics and treatments of infections in transplantation,” report from the 2025 spring highlights in transplantation sciences meeting]]></title>
        <pubdate>2026-08-10T00:00:00Z</pubdate>
        <category>Meeting Report</category>
        <author>Jacques Fourgeaud</author><author>Benedicte Neven</author><author>Nassim Kamar</author><author>Imane Farhat</author><author>Oriol Manuel</author><author>Martina Sester</author><author>Lionel Couzi</author><author>David Boutboul</author><author>Sophie Caillat Zucman</author><author>Jean Daniel Lelievre</author><author>Marie-Benedicte Le Stang</author><author>Marion Le Maréchal</author><author>Hélène François</author><author>Durrbach Antoine</author><author>Julien Zuber</author><author>Hannah Kaminski</author>
        <description><![CDATA[Infectious complications remain a leading cause of morbidity and mortality after solid organ transplantation, driven by profound immunosuppression, emerging pathogens, and increasing antiviral resistance. The 2025 Spring Highlights in Transplantation Sciences (HITS) meeting, held in Paris under the auspices of the Société Francophone de Transplantation and endorsed by the European Society of Organ Transplantation, brought together international experts to discuss recent advances in the diagnosis, pathogenesis, prevention, and treatment of infections in transplant recipients. This report summarizes the key scientific presentations covering innovative approaches to viral hepatitis, cytomegalovirus (CMV), Epstein–Barr virus, human herpesvirus-8, BK polyomavirus, infectious encephalitis, and vaccination strategies. Particular emphasis was placed on the growing role of metagenomic next-generation sequencing for diagnosing unexplained infections, the integration of immune monitoring into clinical decision-making, and the development of adoptive cellular therapies, including virus-specific αβ T cells and γδ T-cell–based immunotherapies for refractory CMV infection. The meeting also highlighted emerging concepts in donor-recipient immunogenetics, novel diagnostic technologies, and personalized preventive strategies. Collectively, these advances illustrate the transition toward precision medicine in transplant infectious diseases, combining cutting-edge diagnostics, immune profiling, and innovative immunotherapeutic approaches to improve the management and outcomes of solid organ transplant recipients.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.17017</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.17017</link>
        <title><![CDATA[Beyond the acceptance decision: integrating genetic findings into lifelong living donor care]]></title>
        <pubdate>2026-08-06T00:00:00Z</pubdate>
        <category>Letter to the Editor</category>
        <author>Stefan Reuter</author><author>Daniela A. Braun</author><author>Klemens Budde</author><author>Barbara Suwelack</author>
        <description></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16046</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16046</link>
        <title><![CDATA[Secondary thrombotic microangiopathy following lung transplantation: a multicenter European cohort study]]></title>
        <pubdate>2026-08-05T00:00:00Z</pubdate>
        <category>Original Research</category>
        <author>Zsofia Rosselli</author><author>Jan Havlin</author><author>Berta Saez-Gimenez</author><author>François M. Carlier</author><author>Gabriella Muraközy</author><author>Peter Jaksch</author><author>Stefan Schwarz</author><author>Dominik Damm</author><author>Mace Schuurmans</author><author>Nicolas Kozakowski</author><author>Martina Gaggl</author><author>Alice Schmidt</author><author>Gere Sunder-Plassmann</author><author>Christof Aigner</author>
        <description><![CDATA[Secondary thrombotic microangiopathy (sTMA) is a rare but severe complication after lung transplantation. We performed a multicenter retrospective cohort study including adult lung transplant recipients diagnosed with de novo sTMA between 2010 and 2023 across five European transplant centers. The primary outcome was incidence of sTMA, with secondary outcomes including clinical presentation, treatment strategies, renal outcomes, and survival. Among 3,747 lung transplantations, 49 cases of sTMA were identified, corresponding to an incidence of 1.33%. Median time to diagnosis was 312 days (IQR 93–546), with 53% occurring within the first post-transplant year. All patients presented with acute kidney injury and laboratory signs of hemolysis, neurological complications were observed in 8%. Therapeutic approaches included plasma exchange (46.9%), anti-C5 therapy (24.5%), and sequential plasma exchange followed by complement inhibition (10.2%). At follow-up, 65.3% developed chronic kidney disease, 20.4% progressed to end-stage renal disease, and 10.2% died during the acute episode. No significant association between treatment modality and renal or survival outcomes was observed. sTMA after lung transplantation is infrequent but associated with substantial renal morbidity and mortality. Early recognition through assessment of hemolysis and kidney injury, supported by renal biopsy in selected cases, may facilitate timely diagnosis and management.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.17121</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.17121</link>
        <title><![CDATA[ABO-incompatibility and hepatocellular carcinoma recurrence after living donor liver transplantation: stratified by tumor burden]]></title>
        <pubdate>2026-08-03T00:00:00Z</pubdate>
        <category>Original Research</category>
        <author>Woo-Hyoung Kang</author><author>Shin Hwang</author><author>Deok-Bog Moon</author><author>Ki-Hun Kim</author><author>Chul-Soo Ahn</author><author>Tae-Yong Ha</author><author>Gi-Won Song</author><author>Dong-Hwan Jung</author><author>Gil-Chun Park</author><author>Young-In Yoon</author><author>Byeong-Gon Na</author><author>Sang-Hoon Kim</author><author>Sung-Min Kim</author><author>Sung-Gyu Lee</author>
        <description><![CDATA[ABO-incompatible (ABOi) living donor liver transplantation (LDLT) requires rituximab-based desensitization and intensified early immunosuppression, and whether this promotes hepatocellular carcinoma (HCC) recurrence remains controversial. We hypothesized that this effect depends on tumor burden, assessed morphologically (Milan criteria) and biologically (ADV score). In this single-center study, we analyzed 1,573 adults transplanted for HCC (ABOi, n = 316; ABO-compatible [ABOc], n = 1,257); the primary endpoint was recurrence-free survival (RFS). Crude recurrence was similar (21.8% vs. 20.7%; P = 0.64) despite a lower tumor burden in ABOi recipients. In a propensity score-matched cohort, RFS did not differ overall (hazard ratio 1.11, 95% CI 0.82–1.48), but beyond Milan recurrence was higher in ABOi recipients (53.7% vs. 38.5%; adjusted HR 1.45, 95% CI 1.00–2.09), whereas within Milan it was identical (13.3% vs. 13.4%). The same pattern held for tumor biology: recurrence was higher in ABOi only at ADV ≥5log (64.0% vs. 44.6%; P = 0.022). Higher early tacrolimus exposure in ABOi recipients was associated with recurrence. Overall survival was similar (P = 0.91). ABO-incompatibility did not compromise survival. Recurrence was higher in ABOi recipients with a high tumor burden by either measure, although the formal interaction tests were not significant (P = 0.23 and P = 0.088). These exploratory subgroup findings are hypothesis-generating and support closer early surveillance.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16516</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16516</link>
        <title><![CDATA[Revealing the potential of non-transplanted donor organs: a comparative analysis in the Eurotransplant region]]></title>
        <pubdate>2026-08-03T00:00:00Z</pubdate>
        <category>Original Research</category>
        <author>A. Kofler</author><author>F. J. Krendl</author><author>L. Prommegger</author><author>J. Hofmann</author><author>A. Weissenbacher</author><author>B. Cardini</author><author>A. T. Meszaros</author><author>T. Resch</author><author>G. Brandacher</author><author>T. Hautz</author><author>R. Oberhuber</author><author>E. de Buijzer</author><author>S. Eschertzhuber</author><author>S. Schneeberger</author>
        <description><![CDATA[Post-mortem organ donation is essential for modern transplantation medicine, yet a substantial proportion of recovered donor organs are not transplanted. These organs, although clinically declined, hold significant and untapped value for biomedical research and technological innovation. Eurotransplant reports and United States national data were reviewed to quantify transplanted and not used organs and to assess temporal trends. During the study period, 100,260 organs were reported in Eurotransplant, of which 32,242 (32.16%) were not transplanted. Of all reported organs, 16.05% were accepted for transplantation but not used, representing a stable and predictable number of organs suitable for secondary research use. A review of international, European, and national legislation demonstrated that, in many Eurotransplant countries, existing laws focus almost exclusively on transplantation and provide limited guidance on the research use of non-transplanted organs, with the Netherlands, Slovenia, Luxembourg, and partially Belgium as notable exceptions. Emerging technologies highlight the scientific and clinical relevance of these organs. Establishing legal and ethical pathways for their secondary use could reduce organ wastage, support innovation, and improve transplantation outcomes. Engagement with the Austrian Federal Ministry of Health, informed by the findings of this work, contributed to an amendment of the Austrian Organ Transplantation Act.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16534</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16534</link>
        <title><![CDATA[Gaza: not to act is to act]]></title>
        <pubdate>2026-07-31T00:00:00Z</pubdate>
        <category>News and Views</category>
        <author>Nizam Mamode</author><author>Susanna Fernandez-Diaz</author><author>Rola Tubail</author><author>Khaled Masoud</author><author>Walid Masoud</author>
        <description></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16565</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16565</link>
        <title><![CDATA[Blood pressure control after solid organ transplantation: opportunities for optimizing care]]></title>
        <pubdate>2026-07-30T00:00:00Z</pubdate>
        <category>Original Research</category>
        <author>A. M. Posthumus</author><author>T. J. Knobbe</author><author>D. Kremer</author><author>M. F. Eisenga</author><author>J. S. F. Sanders</author><author>S. P. Berger</author><author>C. Smit</author><author>F. Klont</author><author>C. T. Gan</author><author>E. A. M. Verschuuren</author><author>K. Damman</author><author>M. H. de Borst</author><author>H. Blokzijl</author><author>S. J. L. Bakker</author><author>V. E. de Meijer</author>
        <description><![CDATA[Hypertension affects 50%–90% of solid organ transplant recipients (SOTR) and is a major driver of cardiovascular disease. Nevertheless, hypertension control has received little attention in this population. We assessed blood pressure control 1 year after heart, liver, lung or kidney transplantation using cross-sectional data from 1112 SOTR (39% female, mean age 57 ± 13 years) from the TransplantLines biobank and cohort study. Suboptimal control was defined as systolic blood pressure >130 mmHg or diastolic blood pressure >80 mmHg. Overall, 997 (90%) SOTR had hypertension. Suboptimal control occurred in 721 (72%), including 146 (20%) who received no antihypertensive treatment despite elevated blood pressure. Rates of suboptimal control were consistently high across organ types (71%–84%). Older age (OR = 1.03; 95%CI1.01–1.04), diabetes (OR = 1.99; 95%CI1.18–3.36), and higher cholesterol (OR = 1.23; 95%CI1.01–1.51) were independently associated with suboptimal control. Among treated SOTR, recipients were older (OR = 1.03; 95%CI1.01–1.05), more often male (OR = 1.55; 95%CI1.03–2.34), and had more prior cardiovascular events (OR = 2.06; 95%CI1.14–3.95). In sensitivity analyses using alternative blood pressure thresholds, suboptimal control remained common, affecting 40% of hypertensive SOTR using a ≤140/90 mmHg threshold. In conclusion, nearly three out of four hypertensive SOTR have suboptimal blood pressure control at 1 year after transplantation with a ≤130/80 mmHg threshold, highlighting a substantial care gap in post-transplant management.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16770</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16770</link>
        <title><![CDATA[Assessing and cataloguing cognitive impairment in older potential kidney transplant patients: key recommendations from the ethical and legal issues working group of ELPAT]]></title>
        <pubdate>2026-07-30T00:00:00Z</pubdate>
        <category>Position Paper</category>
        <author>J. A. Holland</author><author>J. S. L Partridge</author><author>R. L. Thom</author><author>I. Raburn</author><author>D. M. Summers</author><author>A. Ruck Keene</author><author>E. M. Bunnik</author><author>A. J. Cronin</author>
        <description><![CDATA[Cognitive impairment is common in older patients with advanced kidney disease and may influence access to and outcomes from kidney transplantation. However, its assessment and documentation within transplant evaluation remain inconsistent, with important ethical and legal implications. This position paper from the Ethical and Legal Issues Working Group of ELPAT synthesises current evidence, ethical and legal frameworks, and findings from a UK-wide national survey to propose a structured approach to the assessment and documentation of cognitive impairment in older potential kidney transplant recipients. Survey data demonstrate substantial variability in screening practices, documentation, and capacity assessment during transplant workup, contrasting with the standardised evaluation of other transplant domains. Cognitive impairment may affect decision-making capacity, perioperative risk, post-transplant self-management, and graft outcomes, raising important ethical considerations regarding autonomy, equity, and resource allocation. We recommend routine screening using validated tools, standardised documentation within clinical records and registries, use of these data to inform policy and research, prioritisation of cognitive outcomes in future studies, and targeted education and training in cognitive and capacity assessment. Embedding these measures within transplant pathways will support equitable access, informed decision-making, and improved outcomes.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.15958</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.15958</link>
        <title><![CDATA[Prepared or at-risk? Evaluating live viral vaccine coverage and vaccine immunogenicity before pediatric solid organ transplantation]]></title>
        <pubdate>2026-07-29T00:00:00Z</pubdate>
        <category>Original Research</category>
        <author>Benhur Sirvan Cetin</author><author>Caitlin Brammer</author><author>William Otto</author><author>Kerrigan Perkins</author><author>Teresa Ambrosino</author><author>Hilary Miller-Handley</author><author>Mark Murphy</author><author>Grant Paulsen</author><author>Emily Cain</author><author>Kathleen Campbell</author><author>Lara Danziger-Isakov</author>
        <description><![CDATA[Pediatric solid organ transplant recipients are at high risk for complications from vaccine-preventable diseases, yet pre-transplant vaccination coverage is often inconsistent. We conducted a retrospective cohort study of 421 pediatric transplant recipients between 2018 and 2024 to evaluate vaccination status and serologic immunity for varicella and measles at the time of initial evaluation, listing, and transplantation. At the time of transplant, 19.2% of patients for varicella and 21.6% for measles were under-vaccinated, with infants having the highest rates of incomplete vaccination. A portion of patients (7.1% for varicella, 8.6% for measles) transitioned from full to incomplete vaccination status during the pre-transplant period, a change associated with a shorter time from evaluation to listing. Kidney recipients had the highest completed vaccination rates (>94%), whereas rates for liver and heart recipients were substantially lower (58%–72%). Among fully vaccinated patients, seronegativity was observed for varicella (23.6%) and measles (13.0%). In conclusion, many pediatric transplant candidates, particularly infants and those awaiting liver or heart transplant, are incompletely vaccinated. A dynamic change in vaccination status from evaluation to transplant highlights an urgent need for continuous monitoring and improved strategies to protect these vulnerable children.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.17395</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.17395</link>
        <title><![CDATA[Correction: Establishing standards for controlled donation after circulatory determination of death in adults: the Bucharest international European Society for Organ Transplantation consensus]]></title>
        <pubdate>2026-07-29T00:00:00Z</pubdate>
        <category>Correction</category>
        <author>Helen Opdam</author><author>Alicia Pérez-Blanco</author><author>Dale Gardiner</author><author>Richard Hasz</author><author>Nichon Esther Jansen</author><author>Matthieu Le Dorze</author><author>Alberto Sandiumenge</author><author>Giuliano Testa</author><author>Shih-Ning Then</author><author>Marinella Zanierato</author><author>Beatriz Domínguez-Gil</author><author>Gabriel C. Oniscu</author><author>Umberto Cillo</author><author>Dominique E. Martin</author>
        <description></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16491</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16491</link>
        <title><![CDATA[“A shared enemy to confront“: the experience and needs of the partners of kidney transplant patients - a qualitative study]]></title>
        <pubdate>2026-07-29T00:00:00Z</pubdate>
        <category>Original Research</category>
        <author>Katerina Kyriakouli</author><author>Anna Yakinthou</author><author>Smaragdi Marinaki</author><author>Christina Papachristou</author>
        <description><![CDATA[Kidney disease and transplantation affect not only the patients but also their partners, requiring couples and families to adapt to and to cope with complex and ongoing psychosocial and practical demands. Despite playing a crucial role in caregiving and transplant success, partners’ experiences and needs often remain overlooked. This study aimed to explore the lived experiences and needs of partners of kidney transplant recipients in the specific socio-cultural context of the study. Twelve in-depth interviews with partners of kidney transplant patients were conducted and analyzed using thematic analysis. The following themes were identified: 1) The secondary presence: Partners in the background, 2) From Illness to a New Normal, 3) The Need for Support and Clearer Communication from Healthcare Professionals, 4) Redefining the “We” and 5) Transplantation as a Life-Changing Lesson. Findings indicate that partners overtake emotionally complex roles supporting their spouses, yet their difficulties and needs often remain invisible. While going through significant challenges during critical phases of kidney disease, they experience transplantation relationally, through dyadic coping. The shared couple’s experience necessitates a focus on partner’s voices and needs as well as a holistic approach aiming at managing and adapting couples to the transplantation process.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.17398</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.17398</link>
        <title><![CDATA[Retraction: ABO-incompatible liver transplantation for severe hepatitis B patients]]></title>
        <pubdate>2026-07-27T00:00:00Z</pubdate>
        <category>Retraction</category>
        
        <description></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16964</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16964</link>
        <title><![CDATA[Imputed HLA typing as a practical approach to molecular mismatch risk stratification in kidney transplantation]]></title>
        <pubdate>2026-07-23T00:00:00Z</pubdate>
        <category>Letter to the Editor</category>
        <author>Alice Si Hua Ho</author><author>A. Vathsala</author><author>Hersharan Kaur Sran</author><author>Matthew Ross D’Costa</author><author>Zi Yun Chang</author><author>Ada Pei Yu Ng</author><author>Amy Lim</author><author>Wee-Kun Koh</author><author>Emmett Tsz Yeung Wong</author>
        <description></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16391</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16391</link>
        <title><![CDATA[Normothermic regional perfusion (NRP) use in controlled donation after circulatory determination of death (cDCDD): results of the European Society for Organ Transplantation Bucharest consensus conference]]></title>
        <pubdate>2026-07-22T00:00:00Z</pubdate>
        <category>Consensus Report</category>
        <author>Eduardo Miñambres</author><author>Marius Berman</author><author>Marta Velia Antonini</author><author>Jose Luis Campo-Cañaveral De La Cruz</author><author>Kristopher Croome</author><author>Giuseppe Feltrin</author><author>Amelia Hessheimer</author><author>Carl Jorns</author><author>Simon Messer</author><author>Anji Wall</author><author>Beatriz Domínguez-Gil</author><author>Dominique Martin</author><author>Gabriel Oniscu</author><author>Umberto Cillo</author>
        <description><![CDATA[Normothermic Regional Perfusion (NRP) is emerging as a game-changer in enhancing outcomes for Donation after Circulatory Determination of Death (DCDD). NRP maintains physiological conditions through perfusion with oxygenated blood, outperforming conventional super-rapid recovery techniques significantly improving outcomes and organ utilization. Despite its clinical benefits, widespread adoption of NRP is impeded by heterogeneous organizational, legal, and ethical frameworks. At the ESOT Bucharest Consensus Conference, leading experts in transplantation achieved consensus on 130 relevant NRP-related open issues to facilitate its implementation and guide global practice. Key recommendations include criteria for adoption of NRP, minimal requirements, procedures to be adopted before and during NRP, donor organ evaluation criteria and sequence of organ harvesting. Consensus extends to procedural components (including the configuration of perfusion parameters and strategic team coordination), ethical integrity of NRP in the context of the dead donor rule and key unmet needs for future developments. While significant strides were made in unifying practice, unresolved issues regarding maximum warm ischemic time and variability in legal standards indicate avenues for future research. This consensus underscores the imperative for global standardization in NRP application, promising to elevate the success rates of organ transplants and establish NRP as a foundational element in the evolution of DCDD.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16968</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16968</link>
        <title><![CDATA[The European Board of transplant medicine: evolution, present role and future directions toward harmonised transplant medicine training in Europe]]></title>
        <pubdate>2026-07-21T00:00:00Z</pubdate>
        <category>News and Views</category>
        <author>Nuria Montero</author><author>Miha Arnol</author><author>Susanne Beckebaum</author><author>Isabelle Binet</author><author>Vito Cicinnati</author><author>David Cucchiari</author><author>Caroline Den Hoed</author><author>Antoine Durrbach</author><author>Speranta Iacob</author><author>Smaragdi Marinaki</author><author>Anna Paola Mitterhofer</author><author>Anna Mrzljak</author><author>Adam Remport</author><author>Pablo Ruiz</author><author>Susana Sampaio</author><author>Francesca Tinti</author><author>Marios Prikis</author>
        <description></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16734</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16734</link>
        <title><![CDATA[Both perfusion pressure and flow are critical in abdominal normothermic regional perfusion!]]></title>
        <pubdate>2026-07-16T00:00:00Z</pubdate>
        <category>Letter to the Editor</category>
        <author>Raphaël Giraud</author><author>Benjamin Assouline</author><author>Franz Immer</author><author>Yvan Gasche</author><author>Karim Bendjelid</author>
        <description></description>
      </item>
      </channel>
    </rss>